Stockreport

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors [Yahoo! Finance]

Compass Therapeutics, Inc.  (CMPX) 
PDF CTX-8371 is a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1. Compass advanced CTX-8371 to the clin [Read more]